Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva terapia génica para el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20171017001
Publicado:
25/10/2017
Caducidad:
25/10/2018
Resumen:
Una universidad alemana ha desarrollado una nueva terapia para el cáncer basada en un enfoque de edición de genes mediante la inhibición de IkB quinasa. Este método permite la inducción selectiva de la apoptosis en células asociadas a desórdenes proliferativos, como células tumorales. En comparación con otros enfoques, este método aplica secuencias génicas específicas para la IkB quinasa, lo que implica una terapia completamente nueva para el cáncer que abre nuevas opciones incluso en casos de cáncer resistente a medicamentos. La universidad busca socios para establecer acuerdos de licencia.

Details

Tittle:
Novel gene therapy for cancer
Summary:
A German university developed a novel therapy for cancer using a gene editing approach by inhibiting the I¿B kinase. The here presented method allows a selective induction of apoptosis in cells associated with a proliferative disorder. The university offers a license agreement.
Description:
The NF-¿B signaling (nuclear factor ´kappa-light-chain-enhancer´ of activated B-cells) pathway plays a pivotal role in a broad range of cellular processes including cell proliferation and survival and is tightly linked to diseases such as cancer.

The invention of a German university provides compositions comprising IKK1 (I¿B kinase) and IKK2 antagonists for use in medical treatments of proliferative disorders, in particular for the treatment of cancer. Most preferred in context of the invention is a gene editing approach for a targeted simultaneous knockout of the genes of IKK1 and IKK2 in a cell associated with the proliferative disorder.

The herewith presented approach uses the recently invented CRISPR/Cas technology, a DNA sequence forming the basis of genome editing technology to modify genes within organisms. Some companies started to use this technology in the genetic therapy.
Simultaneous CRISPR/Cas9-mediated knockout of IKBKA (IKK1) and IKBKB (IKK2) resulted in cells highly sensitized for programmed cell death (apoptotic/necroptotic) after exposure to tumor necrosis factor (TNF)-a. This effect was not observable in single knockouts for either IKK1 or IKK2. Targeting of IKK1 and IKK2 simultaneously, preferably on the genome level, therefore opens up new therapeutic avenues to tackle proliferative disorders such as cancer. Hence, the present methods and compositions provide a means for the selective induction of apoptosis in cells associated with a proliferative disorder, such as tumor cells.

The university offers a license agreement to companies pursuing genetic approaches in cancer treatment.
Advantages and Innovations:
In comparison to approaches previously used this invention applies specific gene sequences for the I¿B kinase. This leads to a completely novel therapy for cancer that opens up new therapy options even for drug-resistant cancers.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European patent has been filed.

Partner sought

Type and Role of Partner Sought:
The university offers a license agreement.
This technology addresses companies pursuing genetic approaches in cancer treatment. The licensee should want to apply or establish the CRISPR/Cas technology (a DNA sequence that plays a key role in a bacterial defense systemand form the basis of a genome editing technology known as CRISPR/Cas9, that allows permanent modification of genes within organisms.).

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06002003 Tecnología de enzimas